title: Does adding ATG to the GVHD prophylaxis regimen help reduce its incidence?
authors.forename: M
authors.initials: M
authors.lastname: Ayas
authors.forename: Mohamad
authors.initials: M
authors.lastname: Al-Mahr
authors.forename: Abdullah
authors.initials: A
authors.lastname: Al-Jefri
authors.forename: Samira
authors.initials: S
authors.lastname: Rifai
authors.forename: Hassan
authors.initials: H
authors.lastname: Solh
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D005199:Fanconi Anemia / Q000628:therapy*; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D033581:Stem Cell Transplantation / Q000009:adverse effects; D014184:Transplantation, Homologous
chemical_list: D000961:Antilymphocyte Serum